The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 22, 2015

Filed:

Nov. 16, 2012
Applicant:

Adrenomed Ag, Hennigsdorf, DE;

Inventor:

Andreas Bergmann, Berlin, DE;

Assignee:

ADRENOMED AG, Hennigsdorf, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); G01N 33/543 (2006.01); C07K 16/26 (2006.01); G01N 33/68 (2006.01); A61K 31/137 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07K 16/18 (2006.01);
U.S. Cl.
CPC ...
G01N 33/54306 (2013.01); A61K 31/137 (2013.01); A61K 38/1725 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C07K 16/26 (2013.01); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7095 (2013.01);
Abstract

According to the present invention it has been found that the administration of an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold may reduce considerably the risk of mortality in a patient having a severe chronical or acute disease. In a preferred embodiment of the present invention said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds to a region of ADM that is located in the N-terminal part (aa 1-21) of adrenomedullin, (see FIG.). In another preferred embodiment said anti-ADM antibody or anti-ADM fragment or anti-ADM non-Ig scaffold recognizes and binds to the N-terminal end (aa1) of adrenomedullin. N-terminal end means that the amino acid 1, that is 'Y' of SEQ ID No. 21 or 23, is mandatory for antibody binding. The anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold would neither bind N-terminal extended nor N-terminal modified Adrenomedullin nor N-terminal degraded Adrenomedullin in said preferred embodiment.


Find Patent Forward Citations

Loading…